All In MedTech

Device Trial Radar · NCT04523350

Instylla HES Hypervascular Tumor Pivotal Study

Randomized Multi-Center, Subject and Evaluator Blinded, Parallel-Group Study to Evaluate the Safety and Effectiveness of the Instylla Hydrogel Embolic System (HES) Compared With Standard of Care Transcatheter Arterial Embolization (TAE) / Transcatheter Arterial Chemoembolization (cTACE) for Vascular Occlusion of Hypervascular Tumors; A Pivotal Study

Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingTitle says "pivotal". Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

150

Actual

Start

Mar 5, 2021

Primary completion

May 1, 2024

Study completion Nov 19, 2024

Sponsor

Lead sponsor
Instylla, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Aug 21, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine whether Instylla HES has the ability to effectively embolize targeted arterial segments of hypervascular tumors as well as (i.e., is non-inferior to) standard of care (SOC) transarterial embolization/conventional transarterial chemoembolization, while resulting in an acceptable risk of device and procedure-related serious adverse events.

Conditions

  • Hypervascular Tumors

Interventions

  • Instylla HESDevice

    Instylla HES is a novel liquid embolic made of primarily water and polyethylene glycol (PEG)

  • TAE or cTACEOther

    Bland TAE or cTACE

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Effectiveness Endpoint: Delivery of the Embolic Agent to the Index Tumor Feeding Vessel With Stasis of Flow as Determined by an Independent Radiologist Via Comparison of the Pre and Final Post Procedure ImagesTime frame: Immediately post-embolization procedure
  2. Primary Safety Endpoint: Freedom From Major Adverse Events Through 30 Days Post-index ProcedureTime frame: 30 days post-embolization procedure

Locations

15 sites in 2 countries. Site status is shown where the registry gives one.

  • UAB Hospital

    Birmingham, Alabama

  • Central Arkansas Radiation Therapy Institute, Inc.

    Little Rock, Arkansas

  • University of California, Irvine

    Irvine, California

12 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.